217 related articles for article (PubMed ID: 21615820)
1. Prognostic impact of triple negative phenotype in conservatively treated breast cancer.
Barbieri V; Sanpaolo P; Genovesi D
Breast J; 2011; 17(4):377-82. PubMed ID: 21615820
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
4. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.
Zaky SS; Lund M; May KA; Godette KD; Beitler JJ; Holmes LR; O'Regan RM; Yu ES; Yu DS; Landry JC
Ann Surg Oncol; 2011 Oct; 18(10):2858-65. PubMed ID: 21442346
[TBL] [Abstract][Full Text] [Related]
5. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
6. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer.
Parikh RR; Housman D; Yang Q; Toppmeyer D; Wilson LD; Haffty BG
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1056-63. PubMed ID: 18676094
[TBL] [Abstract][Full Text] [Related]
8. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases.
Xu Z; Schlesinger D; Toulmin S; Rich T; Sheehan J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):612-8. PubMed ID: 22436795
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
10. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer.
Li J; Liu X; Tong Z
Jpn J Clin Oncol; 2012 Jun; 42(6):471-6. PubMed ID: 22493058
[TBL] [Abstract][Full Text] [Related]
14. Negative margin status improves local control in conservatively managed breast cancer patients.
Obedian E; Haffty BG
Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases].
Yuan ZY; Wang SS; Gao Y; Su ZY; Luo WB; Guan ZZ
Ai Zheng; 2008 Jun; 27(6):561-5. PubMed ID: 18570725
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast irradiation.
Wilkinson JB; Reid RE; Shaitelman SF; Chen PY; Mitchell CK; Wallace MF; Marvin KS; Grills IS; Margolis JM; Vicini FA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e159-64. PubMed ID: 21345613
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
[TBL] [Abstract][Full Text] [Related]
19. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
20. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]